← Back to Search

Monoclonal Antibodies

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody for Non-Small Cell Lung Cancer (IPSOS Trial)

Phase 3
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6, 12, 18 and 24 months
Awards & highlights

IPSOS Trial Summary

This trial will compare the effectiveness of atezolizumab to chemotherapy in people with lung cancer who are not able to have platinum-doublet chemotherapy.

Eligible Conditions
  • Non-Small Cell Lung Cancer

IPSOS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6, 12, 18 and 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6, 12, 18 and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival (OS)
Secondary outcome measures
Change From Baseline in EORTC QLQ Supplementary Lung Cancer Module 13 (EORTC QLQ-LC13) Score
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) Score
Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1
+8 more

Side effects data

From 2023 Phase 3 trial • 453 Patients • NCT03191786
22%
Decreased appetite
20%
Cough
19%
Fatigue
18%
Dyspnoea
16%
Constipation
16%
Anaemia
14%
Asthenia
13%
Diarrhoea
11%
Pneumonia
11%
Nausea
10%
Pyrexia
10%
Urinary tract infection
10%
Rash
9%
Arthralgia
8%
Hyponatraemia
8%
Back pain
8%
Vomiting
8%
Oedema peripheral
8%
Pruritus
7%
Weight decreased
7%
Hypertension
6%
Haemoptysis
6%
Hypothyroidism
6%
Hypokalaemia
6%
Insomnia
5%
Blood creatinine increased
5%
Dizziness
5%
Headache
4%
Pain in extremity
3%
Pleural effusion
3%
Pneumonitis
2%
Death
2%
Lower respiratory tract infection
2%
Infective exacerbation of chronic obstructive airways disease
2%
Chronic obstructive pulmonary disease
1%
Hyperglycaemia
1%
Acute myocardial infarction
1%
Atrial fibrillation
1%
Respiratory tract infection
1%
Upper respiratory tract infection
1%
Fall
1%
Femoral neck fracture
1%
Femur fracture
1%
Diabetic ketoacidosis
1%
Acute kidney injury
1%
White blood cell count decreased
1%
Sudden cardiac death
1%
Cellulitis
1%
Neutropenia
1%
Immune-mediated hepatitis
1%
Bronchitis
1%
Pneumonia aspiration
1%
Septic shock
1%
Pneumothorax
1%
Pulmonary embolism
1%
Deep vein thrombosis
1%
Leukopenia
1%
Cardiac failure
1%
Hypercalcaemia
1%
Syncope
1%
Confusional state
100%
80%
60%
40%
20%
0%
Study treatment Arm
Atezolizumab
Single Agent Chemotherapy (Vinorelbine or Gemcitabine)

IPSOS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AtezolizumabExperimental Treatment1 Intervention
Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death.
Group II: Single Agent Chemotherapy (Vinorelbine or Gemcitabine)Active Control2 Interventions
Participants will receive single agent chemotherapy; either vinorelbine oral or IV, or gemcitabine IV, according to the label based on investigator's choice.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
2016
Completed Phase 3
~4630

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,426 Previous Clinical Trials
1,088,716 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,197 Previous Clinical Trials
888,144 Total Patients Enrolled

Media Library

Atezolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03191786 — Phase 3
Non-Small Cell Lung Cancer Research Study Groups: Atezolizumab, Single Agent Chemotherapy (Vinorelbine or Gemcitabine)
Non-Small Cell Lung Cancer Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT03191786 — Phase 3
Atezolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03191786 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still enrolling individuals for this clinical trial?

"Unfortunately, this study is not presently enrolling patients. The listing was created on September 11th, 2017 and updated as recently as September 9th, 2022. If you are seeking other studies, there are 2095 clinical trials actively searching for patients with lung cancer and 836 trials for Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody recruiting patients."

Answered by AI

Do many different hospitals offer this research program in town?

"In addition to other research facilities, this study is being conducted at the BCCA-Vancouver Cancer Centre in Vancouver, British Columbia, the Ottawa Hospital Research Institute in Ottawa, Ontario, and the Regional health authority A vitalite health network in Moncton, New Brunswick."

Answered by AI

Are there past examples of MPDL3280A's success in clinical trials?

"As of now, there are a total 836 clinical trials involving Atezolizumab (MPDL3280A), with 210 of those being Phase 3 studies. Many tests are performed in Woolloongabba, Queensland, but there are a total of 42411 locations where these trials take place."

Answered by AI

Has the FDA given their okay to Atezolizumab (MPDL3280A), an antibody that targets PD-L1?

"Atezolizumab (MPDL3280A) is an antibody being trialled for efficacy and safety. So far, it has received a score of 3 from our team at Power."

Answered by AI

What are the FDA-approved indications for Atezolizumab (MPDL3280A)?

"Atezolizumab, an antibody that has been designed to target PD-L1, is most frequently used as a treatment for metastatic ureter urothelial carcinoma. However, it can also be employed to ameliorate conditions such as locally advanced non-small cell lung cancer, recurrent cervical cancer, and malignant neoplasms."

Answered by AI

How many people are enrolled in this clinical research project?

"Unfortunately, this research is no longer enrolling patients in the study. The trial was originally posted on September 11th, 2017 and updated for the last time on September 9th, 2022. However, there are presently 2095 clinical trials actively enrolling participants with lung cancer and 836 studies for Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody admitting patients."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Regional health authority A vitalite health network
What portion of applicants met pre-screening criteria?
Met criteria
~60 spots leftby Mar 2025